INSIGHT - Post Marketing Surveillance

International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC)

In this international non-interventional post-marketing surveillance study we want to evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib (Nexavar®) treatment under daily-life treatment conditions. Specifically investigated are the tumor status, prior and/ or concomitant surgical, radiological and drug treatment and the duration of Sorafenib treatment.

Inclusion Criteria:

• In- and outpatients with diagnosis of hepatocellular carcinoma (HCC) and decision taken by the investigator to prescribe Nexavar

Exclusion Criteria:

• Exclusion criteria must be read in conjunction with the local product information